ClinicalTrials.gg
Active, not recruitingNCT06184633DUTCH-WAISTUpdated Oct 1, 2026

DUTCH Weight Control in Atrial Fibrillation Study

A Phase 4 interventional study of Semaglutide 3.2 MG/ML and Placebo in Atrial Fibrillation, Obesity and Weight Loss, sponsored by Rijnstate Hospital. Active, not recruiting at 20 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Rijnstate Hospital · Phase 4, Interventional, and Treatment

How we know · 4 judgments

Updated Oct 1, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 255 studies in Atrial Fibrillation with a site in Netherlands — 33 open to participants now, 49 under way, 2 of them phase 3. Atrial Fibrillation · Netherlands.

Planned enrollment
88th of 192
280 · median 250
Started
2024
with 12 others
Phase 4
29 of 255
3 open now
Primary completion
2027-04
later than 19 of 48 live
Registered
225th of 255
by date

Among the 255 studies in Atrial Fibrillation with a site in Netherlands, this one is the 88th largest by planned enrollment of the 192 interventional ones that give a count, is one of 13 that started in 2024, is one of 29 in phase 4, reaches primary completion later than 19 of the 48 other live ones, and was the 225th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

33 of the 255 studies in Atrial Fibrillation with a site in Netherlands are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 255 studies in Atrial Fibrillation with a site in Netherlands, or all of them as a file.
02

Study summary

Quantify the effect of an innovative weight loss management on rhythm control.

Read the detailed description

Rationale: Weight reduction promotes reversed atrial remodeling in obese AF patients.

Objective: Quantify the effect of an innovative weight loss management on rhythm control.

Study design: Multi-center, double-blind, randomized, parallel group, placebo-controlled trial of semaglutide 2.4 mg versus placebo.

Study population: Adults with obesity and new onset persistent AF scheduled for electrical cardioversion.

Intervention: semaglutide 2.4 mg subcutaneous (s.c.) once weekly (index) compared to placebo (control), at the background of standard obesity treatment (combined lifestyle intervention) and cardiology follow-up management in both arms.

Main study parameters/endpoints: The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome. The 7 mutually exclusive outcomes hierarchically ranked from worst to best are:

  • Arrhythmic death while using anti-arrhythmic drugs (Vaughn-Williams class I or III)*
  • AF despite pulmonary vein isolation
  • AF despite current use of anti-arrhythmic drugs (Vaughn-Williams class I or III)
  • AF without a pulmonary vein isolation and without the current use of anti-arrhythmic drugs (Vaughn-Williams class I or III)
  • Sinus rhythm on the 12-lead ECG with the use of a pulmonary vein isolation
  • Sinus rhythm on the 12-lead ECG with current use of anti-arrhythmic drugs (Vaughn-Williams class I or III)
  • Sinus rhythm on the 12-lead ECG without the current use of anti-arrhythmic drugs (Vaughn-Williams class I or III) and without a pulmonary vein isolation

    • When LTFU or death other than anti-arrhythmic death, last known rhythm will be used.
03

Conditions studied

  • Atrial Fibrillation
  • Obesity
  • Weight Loss
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic, first detected (at maximum 6 months prior to enrollment) persistent AF -
  • Age ≥ 18
  • Obesity, as defined as:

    • ≥ 30 kg/m2, or
    • BMI ≥27 kg/m2 with the presence of at least one weight related comorbidity (treated or untreated, e.g. hypertension, dyslipidaemia, obstructive sleep apnea, cardiovascular disease)
  • Scheduled ECV
  • Written

Exclusion criteria

Exclusion Criteria:

  • Permanent AF
  • Secondary AF, i.e. due to thyrotoxicosis, infection (e.g. pneumonia) or post-(cardiothoracic) surgery
  • Current or previous treatment with amiodaron
  • ≥ 48 mmol/mol, \<3 months prior to randomization
  • History of diabetes mellitus type 1 or 2
  • Prior bariatric surgery
  • Use of other anti-obesity medication, \<3 months prior to enrollment
  • for, or prior use of a GLP1-receptor agonist
  • History of chronic pancreatitis or acute pancreatitis \<6 months
  • Acute coronary syndrome \<6 months
  • Severe (grade III) valvular disease
  • \<30 mL/min/1.73m2
  • Heart failure class III-IV
  • Participation in another drug or device study in the past 30 days (registry enrollment is allowed)
  • Any condition or therapy, which would make the participant unsuitable for the study (e.g. vulnerable, non-compliance) or life-expectancy \<12 months, as judged by the treating physician.
  • Female who is pregnant, breastfeeding, intends to become pregnant, or is of and not using a highly effective method.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
280 participants (estimated)

Study arms

  • Active comparator
    Intervention

    Semaglutide injections + combined lifestyle intervention

    Drug: Semaglutide 3.2 MG/ML

  • Placebo comparator
    Placebo

    Placebo Semaglutide injections + combined lifestyle intervention

    Drug: Placebo

Interventions

  • DrugSemaglutide 3.2 MG/ML

    Drug page: SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intervention arm receives semaglutide in addition to combined lifestyle intervention

  • DrugPlacebo

    Control arm receives placebo in addition to combined lifestyle intervention

06

What researchers measure

Primary outcomes

  1. The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome

    The 7 mutually exclusive outcomes hierarchically ranked from worst to best are: * Arrhythmic death while using anti-arrhythmic drugs (Vaughn-Williams class I or III)\* * AF despite pulmonary vein isolation * AF despite current use of anti-arrhythmic drugs (Vaughn-Williams class I or III) * AF without a pulmonary vein isolation and without the current use of anti-arrhythmic drugs (Vaughn-Williams class I or III) * Sinus rhythm on the 12-lead ECG with the use of a pulmonary vein isolation * Sinus rhythm on the 12-lead ECG with current use of anti-arrhythmic drugs (Vaughn-Williams class I or III) * Sinus rhythm on the 12-lead ECG without the current use of anti-arrhythmic drugs (Vaughn-Williams class I or III) and without a pulmonary vein isolation * When LTFU or death other than anti-arrhythmic death, last known rhythm will be used.

    Time frame: At 1 year follow-up

Secondary outcomes

  1. Change in AF related symptoms measured by the modified EHRA classification between the index visit and at 12 months after the index visit.

    EHRA: European Heart Rythm Association 1= no symptoms 2a= mild symptoms; Normal dialy activity not affected, symptoms not troublesome to patient 2b= moderate symptoms; Normal daily activity not affected but patient troubled by symptoms 3= severe symptoms; Normal daily activity affected 4= disabling symptoms; Normal daily activity discontinued

    Time frame: week 0 and 52

  2. Change in quality of life measured by the EQ-5D-5L between the index visit and at 12 months after the index visit.

    Descriptive system for health-related quality of life states in adults, consisting of five dimensions (Mobility, Self-care, Usual activities, Pain \& discomfort, Anxiety \& depression), each of which has five severity levels that are described by statements appropriate to that dimension. LEVEL 1: indicating no problem LEVEL 2: indicating slight problems LEVEL 3: indicating moderate problems LEVEL 4: indicating severe problems LEVEL 5: indicating unable to/extreme problems

    Time frame: week 0 and 52

  3. Number of hospitalizations because of an AF recurrence.

    Time frame: week 0-52

  4. Number of unscheduled hospital visits because of adverse events of AAD.

    Time frame: week 0-52

  5. Number of scheduled electrical cardioversions.

    Time frame: week 0-52

  6. Number of unscheduled electrical cardioversions.

    Time frame: week 0-52

  7. Number of intravenous chemical cardioversions (using Vaughan-Williams class I drugs).

    Time frame: week 0-52

  8. Total number of unscheduled cardioverions.

    Time frame: week 0-52

  9. Change in waist circumference, measured in cm

    Time frame: week 0 and 52

  10. Change in weight, measured in % and kg

    Time frame: week 0 and 52

  11. Change in BMI, measured in kg/m2

    Time frame: week 0 and 52

07

Study locations

20 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Apr 2027, 32 months after the start.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 32 months is below that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

Primary completion moved once since we started tracking on Sep 25, 2026: May 2026 → Apr 2027, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2023
First posted
Dec 28, 2023
StartActual
Jul 21, 2024
Primary completionEst.
Apr 10, 2027was May 2026
CompletionEst.
May 1, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 1, 2026
Sites
19 sites added
Show 19 added (19 Netherlands)
  • Jeroen Bosch Ziekenhuis · 's-Hertogenbosch, Netherlands
  • Noordwest Ziekenhuisgroep · Alkmaar, Netherlands
  • Amsterdam UMC · Amsterdam, Netherlands
  • Amphia Ziekenhuis · Breda, Netherlands
  • Deventer Ziekenhuis · Deventer, Netherlands
  • Slingeland Ziekenhuis · Doetinchem, Netherlands
  • Máxima MC · Eindhoven, Netherlands
  • Treant Zorggroep · Emmen, Netherlands
  • Admiraal de Ruyter Ziekenhuis · Goes, Netherlands
  • Martini Ziekenhuis · Groningen, Netherlands
  • Universitair Medisch Centrum Groningen · Groningen, Netherlands
  • Spaarne Gasthuis · Haarlem, Netherlands
  • Zuyderland Medisch Centrum · Heerlen, Netherlands
  • Frisius MC · Leeuwarden, Netherlands
  • Maastricht UMC+ · Maastricht, Netherlands
  • Bravis ziekenhuis · Roosendaal, Netherlands
  • Haaglanden Medisch Centrum · The Hague, Netherlands
  • HagaZiekenhuis · The Hague, Netherlands
  • Diakonessenhuis · Utrecht, Netherlands
Oct 1, 2026
Primary completion
May 1, 2026→Apr 10, 2027
Oct 1, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedHbA1c ≥ 48 mmol/Lmol, <3 months prior to randomization
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Recruiting→Active, not recruiting
    19 sites added
    Show 19 added (19 Netherlands)
    • Jeroen Bosch Ziekenhuis · 's-Hertogenbosch, Netherlands
    • Noordwest Ziekenhuisgroep · Alkmaar, Netherlands
    • Amsterdam UMC · Amsterdam, Netherlands
    • Amphia Ziekenhuis · Breda, Netherlands
    • Deventer Ziekenhuis · Deventer, Netherlands
    • Slingeland Ziekenhuis · Doetinchem, Netherlands
    • Máxima MC · Eindhoven, Netherlands
    • Treant Zorggroep · Emmen, Netherlands
    • Admiraal de Ruyter Ziekenhuis · Goes, Netherlands
    • Martini Ziekenhuis · Groningen, Netherlands
    • Universitair Medisch Centrum Groningen · Groningen, Netherlands
    • Spaarne Gasthuis · Haarlem, Netherlands
    • Zuyderland Medisch Centrum · Heerlen, Netherlands
    • Frisius MC · Leeuwarden, Netherlands
    • Maastricht UMC+ · Maastricht, Netherlands
    • Bravis ziekenhuis · Roosendaal, Netherlands
    • Haaglanden Medisch Centrum · The Hague, Netherlands
    • HagaZiekenhuis · The Hague, Netherlands
    • Diakonessenhuis · Utrecht, Netherlands
    Primary completion May 1, 2026→Apr 10, 2027
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedHbA1c ≥ 48 mmol/Lmol, <3 months prior to randomization
    + 4 other changes: index terms, verification date, contact details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06184633
Lead sponsor
Rijnstate Hospital
Responsible party
Ron Pisters (Head of Cardioresearch and principal investigator, dr. R. Pisters, Rijnstate Hospital) — Principal investigator
First posted
Dec 28, 2023
Start date
Jul 21, 2024
Primary completion
Apr 10, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Ron Pisters, dr.
principal investigator · Rijnstate Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion